Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ADC Therapeutics SA is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. ADC Therapeutics employs 208 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$28.29|
|52-week range||$20.01 - $46.20|
|50-day moving average||$26.67|
|200-day moving average||$24.39|
|Wall St. target price||$43.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.67|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-1.98%|
|1 month (2021-08-25)||9.40%|
|3 months (2021-06-25)||12.80%|
|6 months (2021-03-25)||7.12%|
|1 year (2020-09-25)||-15.75%|
|2 years (2019-09-21)||N/A|
|3 years (2018-09-21)||N/A|
|5 years (2016-09-21)||N/A|
|Revenue TTM||$3.8 million|
|Gross profit TTM||$-141,816,000|
|Return on assets TTM||-40.47%|
|Return on equity TTM||-91.02%|
|Market capitalisation||$2.3 billion|
TTM: trailing 12 months
There are currently 6.0 million ADC Therapeutics shares held short by investors – that's known as ADC Therapeutics's "short interest". This figure is 11.2% up from 5.4 million last month.
There are a few different ways that this level of interest in shorting ADC Therapeutics shares can be evaluated.
ADC Therapeutics's "short interest ratio" (SIR) is the quantity of ADC Therapeutics shares currently shorted divided by the average quantity of ADC Therapeutics shares traded daily (recently around 301907.22528851). ADC Therapeutics's SIR currently stands at 19.93. In other words for every 100,000 ADC Therapeutics shares traded daily on the market, roughly 19930 shares are currently held short.
However ADC Therapeutics's short interest can also be evaluated against the total number of ADC Therapeutics shares, or, against the total number of tradable ADC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADC Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ADC Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2042% of the tradable shares (for every 100,000 tradable ADC Therapeutics shares, roughly 204 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ADC Therapeutics.
Find out more about how you can short ADC Therapeutics stock.
We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B. V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. .
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.